The Effects of Combined Antihypertensive and Antidiabetic Therapies on Cardiovascular Outcomes: A Systematic Review and Meta‐Analysis
Diabetes, Obesity and Metabolism · 2026-08 · 28 (8) · 6874-6887
DOI: 10.1111/dom.70907 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 20.05.2026. Verfasst von Wan Chin Hsieh und 2 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of Debrecen, Debrecen, Hungary. Hauptthemen laut MEDLINE: Antihypertensive Agents, Hypoglycemic Agents, Hypertension, Cardiovascular Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Aims
Hypertension and diabetes frequently coexist, yet the net clinical impact of intentionally combining antihypertensive (AHTN) and antidiabetic (ADA) therapies on cardiovascular (CV) outcomes is uncertain. Here we quantified the effects of AHTN and ADA co‐therapy on CV and blood pressure (BP)/heart rate (HR) outcomes.
Methods
The MEDLINE, Embase, and Scopus databases were searched from database inception through November 2025. Eligible studies were randomised controlled trials (RCTs) comparing combined AHTN+ADA versus AHTN or ADA alone and reporting CV events and/or (BP)/(HR) outcomes. Risk ratios (RRs) and mean differences (MDs) with 95% CIs were pooled using random‐effects models. A prespecified exploratory analysis synthesised CV outcome trials of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) versus placebo.
Results
Nine RCTs ( n = 13 955 subjects) met inclusion criteria. Compared with AHTN alone, AHTN+ADA reduced composite CV events as defined in each trial, CV death, and HF hospitalisation. Combination therapy achieved modest but significant BP reductions (systolic −2.57 mmHg; diastolic −1.03 mmHg) without excess risk of hypotension, and HR effects were combination specific. Exploratory analysis of seven GLP‐1 RA trials ( n = ~56 000) showed reductions in composite CV events and CV death versus placebo, but no effect on HF hospitalisation.
Conclusions
AHTN+ADA co‐therapy was associated with improved CV outcomes and modest BP reduction compared with monotherapy, with effects predominantly driven by SGLT2 inhibitor‐based combinations. Exploratory evidence indicates that GLP‐1 RAs provide complementary reductions in CV outcomes and mortality but not HF events. Together, these findings support phenotype‐guided integration of ADA with guideline‐directed AHTN in cardiometabolic disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
- Clinical Laboratory, Division of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
- Department of Cardiology and Cardiac Surgery, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
ORCID-Profile: Wan Chin Hsieh
Zitieren
APA
Hsieh, W. C., Henry, B. M., & Édes, I. (2026). The Effects of Combined Antihypertensive and Antidiabetic Therapies on Cardiovascular Outcomes: A Systematic Review and Meta‐Analysis. Diabetes, Obesity and Metabolism, 28(8), 6874-6887. https://doi.org/10.1111/dom.70907
Vancouver
Hsieh WC, Henry BM, Édes I. The Effects of Combined Antihypertensive and Antidiabetic Therapies on Cardiovascular Outcomes: A Systematic Review and Meta‐Analysis. Diabetes, Obesity and Metabolism. 2026;28(8):6874-6887. doi:10.1111/dom.70907
BibTeX
@article{Hsieh2026,
author = {Hsieh, Wan Chin and Henry, Brandon Michael and Édes, István},
title = {The Effects of Combined Antihypertensive and Antidiabetic Therapies on Cardiovascular Outcomes: A Systematic Review and Meta‐Analysis},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
volume = {28},
number = {8},
pages = {6874--6887},
doi = {10.1111/dom.70907}
}
EUVIMED